Free Trial

PureTech Health (LON:PRTC) Stock Price Up 14.2% - What's Next?

PureTech Health logo with Medical background

Key Points

  • PureTech Health's shares surged 14.2% during trading, reaching a high of GBX 123.80 ($1.67) as trading volume jumped to approximately 9 million shares, significantly higher than the average daily volume.
  • The company has a market capitalization of £293.65 million and a P/E ratio of 714.71, indicating a highly valued stock relative to its earnings.
  • Insider Bharatt Chowrira acquired 167,739 shares at £1 each, highlighting ongoing insider confidence in the company as they own 13.13% of PureTech Health's stock.
  • MarketBeat previews top five stocks to own in November.

PureTech Health plc (LON:PRTC - Get Free Report)'s share price shot up 14.2% during trading on Saturday . The stock traded as high as GBX 123.80 ($1.67) and last traded at GBX 121.50 ($1.64). 9,013,305 shares were traded during mid-day trading, an increase of 1,053% from the average session volume of 781,543 shares. The stock had previously closed at GBX 106.40 ($1.44).

PureTech Health Price Performance

The company has a debt-to-equity ratio of 45.82, a quick ratio of 2.51 and a current ratio of 3.68. The firm's 50-day moving average is GBX 129.31 and its 200 day moving average is GBX 129.65. The firm has a market capitalization of £303.07 million, a PE ratio of 737.65 and a beta of 1.02.

Insider Buying and Selling at PureTech Health

In other PureTech Health news, insider Bharatt Chowrira acquired 167,739 shares of the company's stock in a transaction dated Thursday, July 3rd. The stock was acquired at an average cost of GBX 1 per share, with a total value of £1,677.39. 13.13% of the stock is currently owned by company insiders.

PureTech Health Company Profile

(Get Free Report)

PureTech Health plc, a clinical-stage biopharma company, focuses on developing medicines for diseases caused by dysfunctions in the nervous, gastrointestinal, and immune systems. The company is developing a microbiome immune system drug-discovery platform and drug candidates for immune-mediated diseases; and products to induce weight loss and enhance glycaemic control through an orally administered capsule.

Further Reading

Should You Invest $1,000 in PureTech Health Right Now?

Before you consider PureTech Health, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and PureTech Health wasn't on the list.

While PureTech Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report
Like this article? Share it with a colleague.